NEWS & MEDIA

We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.

PRESS RELEASES

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination...

read more

BeyondSpring Files 2020 Annual Report on Form 20-F

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form...

read more

MEDIA

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.